Compositions and methods for delivery of hydrophobic active agents
Disclosed herein is a delivery composition for administering a hydrophobic active agent. In one embodiment, a delivery composition for local administration of a hydrophobic active agent to a tissue or organ of a patient is disclosed. In one embodiment, the delivery composition includes a cationic delivery agent, a therapeutically effective amount of a hydrophobic active agent and a pharmaceutically acceptable aqueous carrier. In one embodiment, the cationic delivery agent includes polyethyleneimine (PEI). In an embodiment, the invention includes a drug delivery device including a substrate; and coated therapeutic agent particles disposed on the substrate, the coated therapeutic agent particles comprising a particulate hydrophobic therapeutic agent; and a vinyl amine polymer. Methods of making the delivery composition, as well as kits and methods of use are also included herein.
1. A drug delivery device comprising:
a substrate;
an uncharged hydrophilic polymer layer disposed on the substrate, the uncharged hydrophilic polymer layer comprising a biostable synthetic hydrophilic polymer comprising one or more of acrylic monomers, vinyl monomers, and ether monomers; and
a coated therapeutic agent particle layer disposed on the uncharged hydrophilic polymer layer, the coated therapeutic agent particle layer consisting of coated therapeutic agent particles comprising:
a particulate hydrophobic therapeutic agent; and
PVP-co-pNVA at a mol fraction of 20:80 PVP:pNVA to 80:20 PVP:pNVA; and
wherein the coated therapeutic agent particle layer is configured as an outermost layer of the drug delivery device for direct contact with an in vivo environment.
2. The drug delivery device of claim 1 , the coated therapeutic agent particles exhibiting a Zeta potential of greater than +10 mV.
3. The drug delivery device of claim 1 , the particulate hydrophobic therapeutic agent having an average diameter of between 100 nm and 10 μm.
4. The drug delivery device of claim 1 , the particulate hydrophobic therapeutic agent having an average diameter of between 0.3 μm to about 1 μm.
5. The drug delivery device of claim 1 , the particulate hydrophobic therapeutic agent selected from the group consisting of paclitaxel, sirolimus, and analogs thereof.
6. The drug delivery device of claim 1 , the uncharged hydrophilic polymer layer covalently bonded to the substrate.
7. The drug delivery device of claim 1 , the uncharged hydrophilic polymer layer cross-linked with a photoactivatable cross-linking agent.
8. The drug delivery device of claim 1 , the device comprising a drug-containing balloon catheter.
9. A drug delivery coating comprising
a polymeric layer, the polymeric layer comprising an uncharged hydrophilic surface configured to be disposed on a substrate, the uncharged hydrophilic polymer layer comprising a biostable synthetic hydrophilic polymer comprising one or more of acrylic monomers, vinyl monomers, and ether monomers;
a coated therapeutic agent particle layer disposed on the hydrophilic surface, the coated therapeutic agent particle layer consisting of coated therapeutic agent particles comprising:
a particulate hydrophobic therapeutic agent core; and
PVP-co-pNVA at a mol fraction of 20:80 PVP:pNVA to 80:20 PVP:pNVA; and
wherein the coated therapeutic agent particle layer is configured as an outermost layer of the drug delivery device for direct contact with an in vivo environment.
10. A medical device comprising:
a capsule housing;
control circuitry disposed with in the capsule housing;
at least one moveable element operably connected to the capsule housing,
the moveable element comprising
a substrate and
a coating disposed on the substrate, the coating comprising;
an uncharged hydrophilic polymer layer disposed on the substrate, the uncharged hydrophilic polymer layer comprising a biostable synthetic hydrophilic polymer comprising one or more of acrylic monomers, vinyl monomers, and ether monomers; and
a coated therapeutic agent particle layer disposed on the hydrophilic polymer layer, the coated therapeutic agent particle layer consisting of coated therapeutic agent particles comprising:
a particulate hydrophobic therapeutic agent; and
PVP-co-pNVA at a mol fraction of 20:80 PVP:pNVA to 80:20 PVP:pNVA; and
wherein the coated therapeutic agent particle layer is configured as an outermost layer of the drug delivery device for direct contact with an in vivo environment.
11. The medical device of claim 10 , the control circuitry configured to cause the moveable element to move between a deployed position and a non-deployed position; the medical device comprising a total width, wherein the total width of the medical device is greater in the deployed configuration than in the non-deployed configuration.
12. The drug delivery device of claim 1 , further comprising PVP-co-pNVA at a mol fraction of 40:60 PVP:pNVA to 60:40 PVP:pNVA.
13. The drug delivery device of claim 1 , further comprising PVP-co-pNVA at a mol fraction of 50:50 PVP:pNVA.